214759-95-2

Usage

Uses

Used in Pharmaceutical Industry:
N-Methoxy-N-methyl-1H-indole-3-carboxamide is used as a potential anticancer agent for its potential to target and treat cancer cells. Its specific biological activity and pharmacological properties are under investigation to determine its full therapeutic potential.
Used in Organic Chemistry:
In the field of organic chemistry, N-Methoxy-N-methyl-1H-indole-3-carboxamide serves as a building block for the synthesis of novel pharmaceutical compounds, contributing to the development of new drugs and therapeutic agents.
Further research is necessary to fully understand the potential uses and effects of N-methoxy-N-methyl-1H-indole-3-carboxamide, including its role in drug discovery and development.

Upstream product

• 771-50-6 1H-indole-3-carboxylic acid 
• 79-37-8 oxalyl dichloride 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 675606-20-9 1-(tert-butoxycarbonyl)-1H-indole-3-carboxylic acid 
• 3973-08-8 Thiazole-4-carboxylic acid 

Downstream Products

• 448906-42-1 ITE 

Relevant academic research and scientific papers

PROCESSES FOR THE PREPARATION OF ARYL HYDROCARBON RECEPTOR LIGANDS

The present disclosure relates to the preparation of methyl 2-(1H-indole-3-carbonyl)thiazole-4-carboxylate (ITE) and related compounds with high yield, purity, and scalability. The processes apply the use of a Weinreb amide intermediate as a scaffold for the preparation of ITE and structural analogs.

Rh2(II)-catalyzed nitro-group migration reactions: Selective synthesis of 3-nitroindoles from β-nitro styryl azides

Rhodium carboxylate complexes (1 mol %) catalyze the migration of electron-withdrawing groups to selectively produce 3-substituted indoles from β-substituted styryl azides. The relative order of migratorial aptitude for this transformation is ester ? amide H sulfonyl benzoyl ? nitro.

5-HT4 receptor antagonist

Compounds of formula (I) and pharmaceutically acceptable salts thereof, and the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein X is a monocyclic or polycyclic aromatic group, Z is of sub-formula (h), (j) or (k): STR1 wherein n1 is 1, 2, 3 or 4; n2 is 0, 1, 2, 3 or 4; n3 is 2, 3, 4 or 5; q is 0, 1, 2 or 3; p is 0, 1 or 2; m is 0, 1 or 2; R5 is hydrogen, C1-12 alkyl, aralkyl or R5 is (CH2)z --R10 wherein z is 2 or 3 and R10 is selected from cyano, hydroxyl, C1-6 alkoxy, phenoxy, C(O)C1-6 alkyl, COC6 H5, --CONR11 R12, NR11 COR12, SO2 NR11 R12 or NR11 SO2 R12 wherein R11 and R12 are hydrogen or C1-6 alkyl; or R5 is straight or branched chain alkylene of chain length 1-6 carbon atoms terminally substituted by aryl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 5 or 6 membered monocyclic heteroaryl or 9 or 10 membered fused bicyclic heteroaryl linked through carbon, C2-7 alkoxycarbonyl, or secondary or tertiary hydroxy substituted C1-6 alkyl; and R6, R7 and R8 are independently hydrogen or C1-6 alkyl; and R9 is hydrogen or C1-10 alkyl; and their use as pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and CNS disorders are provided.